Mid Cap Healthcare
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
151
Inspire Medical Systems
INSP
$2.04B
| $2.04B | $70.50 | 2.46% |
|
152
Vericel Corp
VCEL
$2.03B
| $2.03B | $39.71 | 1.04% |
|
153
Kodiak Sciences
KOD
$2.03B
| $2.03B | $32.35 | 2.62% |
|
154
UroGen Pharma
URGN
$2.02B
| $2.02B | $41.35 | 0.29% |
|
155
Nuvation Bio
NUVB
$2.02B
| $2.02B | $5.74 | 0.17% |
|
156
Recursion Pharmaceuticals
RXRX
$2.01B
| $2.01B | $3.74 | 3.86% |
|
Mid Cap Healthcare Stocks at a Glance
Healthcare companies develop drugs, build medical devices, run hospitals and insurers, and supply the systems behind patient care. Demand is largely non-discretionary, but returns hinge on drug-pipeline outcomes, patent lives, and reimbursement policy — a mix of defensive services and high-risk, high-reward research bets.
There are 156 mid cap Healthcare stocks — companies in the Healthcare sector with a market cap between $2B and $10B — worth a combined $696B.
The largest by market cap are Molina Healthcare (MOH) at $9.96B, Bruker (BRKR) at $9.78B and Henry Schein (HSIC) at $9.63B.
Among institutional investors, Definium Therapeutics (DFTX) drew the most net new fund positions in Q2 2026: 148 funds opened new positions, taking total fund holders up 114 (46%) quarter-over-quarter.
- Combined market cap: $696B across 156 stocks.
- Mid Cap: market cap between $2B and $10B.
- Largest constituent: Molina Healthcare (MOH), $9.96B market cap.
- Most net new fund positions in Q2 2026: Definium Therapeutics (DFTX), +114 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.